15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Oncolytics Biotech Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $7.00 to $10.00, a moderate spread. The average target of $8.50 sits 976% above the current $0.79. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Strong Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Oncolytics Biotech Inc.
As of Jul, 2 of 2 firms rate ONCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ONCY EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.08 – $-0.07 · 4 analysts · -45% YoY
Next period, 4 analysts expect Oncolytics Biotech Inc to earn $-0.08 a share (range $-0.08 – $-0.07), versus $-0.14 a year earlier. Full-year consensus is $-0.34, growing to $-0.34 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Oncolytics Biotech Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ONCY.
#1
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$10.00+1165.7% to target
Overall win rate
35%
+ Follow
#2
Jason McCarthy
Maxim Group · Rank #360
Buy
$3.00+279.7% to target
Overall win rate
30%
+ Follow
#3
DM
Douglas Miehm
RBC Capital
Buy
$3.50+343.0% to target
Coverage
—
+ Follow
#4
DL
Douglas Loe
Leede Financial
Buy
$4.00+406.3% to target
Coverage
—
+ Follow
#5
CM
Chad Messer
Lake Street
Buy
$7.00+786.0% to target
Coverage
—
+ Follow
ONCY stock forecast FAQ
What is ONCY's average 12-month price target?+
The 2 analysts with a live target average $8.50 for Oncolytics Biotech Inc over the next 12 months, ranging from a $10.00 high to a $7.00 low.
Is ONCY stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ONCY?+
The Street-high target is $10.00 (HC Wainwright & Co.), and the Street-low is $7.00 (Lake Street). The average of all 2 active targets is $8.50.
How many Wall Street analysts cover ONCY?+
2 analysts have an active rating on Oncolytics Biotech Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering ONCY?+
Among analysts who currently cover ONCY, Patrick R. Trucchio of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #203). Their current call is Buy with a $10.00 target.
What is Oncolytics Biotech Inc's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.08 – $-0.07) across 4 analysts. Full-year EPS is projected at $-0.34, rising to $-0.34 the following year.
How much revenue is Oncolytics Biotech Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ONCY lately?+
As of Jul, 2 of 2 firms rate ONCY a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ONCY calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
